Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair® Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4898676_CN98676_0